Recurrent ventricular tachycardias are associated with a high mortality in patients with underlying heart disease.1 2 Since empirically chosen antiarrhythmic drug treatment is often ineffective, electrophysiological testing of such drug treatment was proposed for these patients. [3] [4] [5] Nevertheless, the choice of antiarrhythmic drugs remains empirical, and the comparative efficacy of customarily used drugs for control of sustained ventricular tachycardias has not yet been readily assessed. Therefore, this study compares the effects of the commonly used antiarrhythmic agents mexiletine and disopyramide on inducibility and rate of recurrent sustained ventricular tachycardia.
Patients and methods
Mexiletine and disopyramide were given to 34 out of 45 patients, who underwent consecutive electrophysiological studies for the evaluation of recurrent persistent ventricular tachyarrhythmias between May
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Accepted for publication 21 September 1982 1979 and August 1981. The clinical data of these 34 patients are listed in Table 1 . All patients except case 8 had been referred to our institution from other hospitals for comprehensive evaluation and prescription of antiarrhythmic drugs. All patients had at least one documented spontaneous episode of symptomatic ventricular tachycardia (ranging from one to 80) that was sustained for minutes and usually required pharmacological or electrical conversion (mean DC cardioversions 5.9, ranging from 0 to 45).
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FOLLOW-UP
Seven patients were maintained on chronic oral treatment with mexiletine for a mean of 26 months±5. Two of the three patients, whose arrhythmias were suppressed during the electrophysiological study, did not experience persistent ventricular tachycardias again for 20 months (case 16) and 29 months (case 15).
In the third patient, mexiletine was discontinued because of a rise of liver enzymes. Though still inducible by double premature stimuli, persistent ventricular tachycardia did not return in one further patient for 24 months (case 12). On the other hand, three patients, still inducible, died suddenly: one in the hospital (case 25), one after three months (case 7), and the third after 25 months (case 8).
Twelve patients were chronically treated with disopyramide for 22 months±9. The patient with total suppression of the ventricular tachycardia has been free from further attacks until now for 32 months (case 4). In case 9 with repetitive response, sustained tachycardias returned, were self-terminating, however, and less frequent. One further patient has also been free from ventricular tachycardias for 18 months so far (case 14). Recurrences of ventricular tachycardias were observed in eight patients but with a distinct reduction of frequency.
Documented recurrences of three of these patients showed a slow rate similar to the electrophysiologically induced ventricular tachycardia. Three patients died: one patient had three spontaneously terminating tachycardias and died suddenly 11 months later (case 11). One died because of pulmonary embolism after eight months; in the meantime, three spontaneously terminating tachycardias recurred (case 12). The third patient had no relapse until he died suddenly because of ventricular fibrillation after nine months (case 13).
ADVERSE EFFECTS
During mexiletine treatment, one patient complained about nausea that did not necessitate a change in treatment. Laboratory data of one patient indicated hepatic dysfunction so that treatment was discontinued though the rise of the liver enzymes could not be attributed with certainty to the drug. In the other patients, the drug was well tolerated. Disopyramide produced a pronounced negative inotropic effect in three patients; in one patient, low output failure occurred, which had to be controlled by catecholamine infusion. Two men experienced urinary retention. One patient reported dizziness.
Discussion

INDUCIBILITY
Complete suppression of sustained ventricular tachycardias by oral mexiletine or disopyramide during programmed stimulation could be accomplished in a minority of our patients only. In other series, complete suppression was reached in eight of 1210 and in one of five5 by disopyramide, and in two out of 12 patients with sustained tachycardia by mexiletine" ; a somewhat higher dose of either compound was administered. Comparing these data with our results, an increase of dosage, especially of mexiletine, could have led to a slightly higher percentage of complete suppression.
A major reason for the low rate of complete suppression appears to be the highly selected group of patients with tachycardias previously resistant to several antiarrhythmic agents, as listed in Table 1 . From our results, these patients, resistant in particular to other class I antiarrhythmic agents, respond rarely to mexiletine and disopyramide.
RATE OF VENTRICULAR TACHYCARDIA
The rate of ventricular tachycardias was not significantly influenced by mexiletine, as in previous studies. 12 In individual patients, a distinct increase of rate was\ observed. Similar observations have been reported under the influence of phenytoin and lignocaine.'3 In contrast to mexiletine, disopyramide decreased considerably the rate of ventricular tachycardias. A similar decrease in the rate of ventricular tachycardia has been observed in individual patients.5 14 In the study of Benditt et al. 1O and of Breithardt et al. 12 the decrease in the rate of tachycardia was not significant, however; this disparity might be because of the small sample size in these studies. If in a given patient complete suppression cannot be achieved, lowering the rate of the tachycardia-for example with disopyramide-is a major goal of treatment, so that the tachycardia is tolerated haemodynamically until medical assistance is available.
SPONTANEOUS RECURRENCES
Tentative conclusions only can be drawn from the follow-up of our patients, since a selected subgroup was maintained on chronic treatment. Patients with complete suppression showed an excellent prognosis even after a follow-up of two years. In the group of patients with tachycardias still inducible, most patients experienced recurrences, but less frequently and at a lower rate. On the other hand, one third of the patients died suddenly after a mean of two years. Whether the clinical course of such patients can be favourably influenced by alternative treatments such as other drugs or antiarrhythmic cardiac surgery is the subject of current investigations.
LIMITATIONS OF STUDY
The present investigation is a retrospective study, and the study groups are not identical. Therefore, conclusions considering effectiveness and prognosis have to be drawn cautiously. For statistical analysis, however, only those patients were considered who were treated with either substance.
During programmed ventricular stimulation premature ventricular complexes, delivered by the stimulation unit, start the ventricular tachycardia. In this way, ventricular stimulation evaluates the ability of the re-entrant circuit to perpetuate ventricular tachycardia under the influence of antiarrhythmic drugs. The influence of antiarrhythmic drugs on the spontaneous ventricular complexes for initiation of tachycardias was not assessed.
Nevertheless, several previous studies have shown that programmed ventricular stimulation fairly predicted the clinical outcome, as in this report. 3 
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Whether quantitative analysis of spontaneous ventricular arrhythmias in these special patients is of additional value for prediction of antiarrhythmic efficacy, needs further investigations. 
